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CD28 antagonistsAutoimmuneuveitis is an organ-speciﬁc disorder characterized by irreversible lesions to the eye that predominantly
affect people in theirmost productive years and is among the leading causes of visual deﬁcit andblindness. Currently
available therapies are effective in the treatment of a wide spectrum of uveitis, but are often associated with severe
side effects. Here, we review ongoing research with promising immunomodulatory therapeutic strategies, describ-
ing their speciﬁc features, interactions and the responses triggered by the targeted immune molecules that aim to
minimize clinical complications and the likelihood of disease relapse. We ﬁrst review the main features of the dis-
ease, diagnostic tools, and traditional forms of therapy, as well as the animal models predominantly used to under-
stand the pathogenesis and test the novel intervention approaches aiming to control the acute immune and
inﬂammatory responses and to dampen chronic responses. Both exploratory research and clinical trials have
targeted either the blockade of effector pathways or of their companion co-stimulatory molecules. Examples of tar-
gets are T cell receptors (CD3), their co-stimulatory receptors (CD28, CTLA-4) and corresponding ligands (B7-1 and
B7-2, also known as CD80 and CD86), and cytokines like IL-2 and their receptors. Here, we summarize the available
evidence on effectiveness of these treatments in human and experimental uveitis and highlight a novel CD28 antag-
onist monovalent Fab′ antibody, FR104, which has shown preclinical efﬁcacy suppressing effector T cells while en-
hancing regulatory T cell function and immune tolerance in a humanized graft-versus-host disease (GVHD) mice
model and is currently being tested in a mouse autoimmune uveitis model with encouraging results.
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Autoimmune disorders encompass a wide range of chronic inﬂam-
matory conditions and are among the leading causes of disability in
the world (report from The Autoimmune Diseases Coordinating Com-
mittee of the National Institutes of Health, 2005 at http://www.niaid.
nih.gov/topics/autoimmune/research/Pages/coordComm.aspx, updated
April 30, 2012). These diseases are characterized by an abnormal re-
sponse of the immune system, which failing to distinguish self from
non-self-molecules reacts against organs, tissues and cells of the indi-
vidual. Although the speciﬁc mechanisms triggering each type of auto-
immune disease are not completely understood, it is well established
that the development and progression of autoimmune disorders is
strongly associated with both genetic and environmental factors,
which predispose the individual to the disease.
Although each speciﬁc autoimmune condition has usually a low inci-
dence, collectively autoimmune disorders affect 14.7 to 23.5 million peo-
ple in the United States (http://www.niaid.nih.gov/topics/autoimmune,
updated August 1, 2013) alone. The high burden of autoimmune diseases
is exacerbated by the chronic character of these conditions, the impair-
ment in the quality of life of patients and the cost of the available treat-
ments. More effective, safer and affordable therapies targeted at speciﬁc
molecules and conditions would be ideal characteristics of a good treat-
ment, several of which are under development, but are currently still
not available.
Much clinical and experimental research on autoimmune diseases is
directed towards the investigation of novel therapies or the improve-
ment of currently available treatments. Owing to the great variability
in the mechanisms underlying disease development and progression,
current studies focus on the understanding of speciﬁc features andmo-
lecular pathways associated with each disorder. In particular, the use of
therapies targeted at rare or distinctive autoimmune diseases currently
represents promising areas of study. One such disease is autoimmune
uveitis, an organ-speciﬁc disorder characterized by irreversible lesions
to the eye. Autoimmune uveitis (AIU) predominantly affects people in
their most productive years (from 20 to 50 years of age), and is
among the leading causes (approximately 10% of all cases) of visual def-
icit and blindness. AIU has an incidence of 52.4 per 100,000 and a prev-
alence of 115.3 per 100,000 habitants in the United States [1], and is also
considered a global socioeconomic problem (The International Uveitis
Study Group— http://www.iusg.net, updated November 16, 2013).
The heterogeneity of underlying factors and the variable disease se-
verity of AIU patients reinforce the need for an accurate diagnosis. Al-
though currently available therapies are effective in the treatment of a
wide spectrum of uveitis, most are associated with important and se-
vere side effects. In this sense, treatments based on novel molecules or
employing well-known molecules, tuning their use to the various hier-
archical levels of the immune response, represent promising avenues of
research. Moreover, the investigation of alternative or combined treat-
ments focusing on groups of patients with a similar disorder may be
also fruitful.
Here, we review ongoing research to treat AIU with promising im-
munomodulatory therapeutic strategies, highlighting their speciﬁc fea-
tures, interactions and the responses triggered by the targeted immune
molecules that aim to minimize clinical complications and the likeli-
hood of disease relapse. For improved comprehension we ﬁrst review
the main features of AIU, diagnostic tools and traditional forms of ther-
apy, as well the animal models predominantly used to understand its
pathogenesis and test novel intervention approaches.
2. Autoimmune uveitis
Uveitis is an inﬂammation of the uvea, a layer located between the
sclera and the retina of the eye that includes the iris, ciliary body, and
choroid, but can also extend to adjacent tissues, such as retina, optic
nerve, and vitreous humor [2]. The disease is broadly classiﬁed intoinfectious and non-infectious (which includes AIU) uveitis and in
humans, can affect the anterior, intermediate, and posterior portions
of the eye [3]. Furthermore, a series of autoimmune diseases may addi-
tionally present uveitis, with overlapping AIU features but also unique
characteristics. That is the case for Behçet's disease [4], reactive arthritis
[5], sarcoidosis [6], and Vogt–Koyanagi–Harada syndrome [7,8]. In con-
trast, AIU is conﬁned to the eye.
In AIU, ocular antigens such as arrestin also known as S-antigen [9],
the interphotoreceptor retinoid binding protein IRBP, and/or recoverin
[10] are exposed and an immune response against thesemolecules is ini-
tiated [11]. Among the events involved in this response, blood–retinal
barrier disruption and retinal antigen recognition by auto-reactive T
cells are critical elements. In addition, predisposing MHC class II alleles
have been identiﬁed in some populations, namely, HLA-DR4, HLA-DR3
and some HLA-DQ alleles [12]. Under normal conditions, special micro-
anatomical features that characterize the so-called immune privilege of
the eye [13] ensure that retinal molecules are protected from autoim-
mune responses and that tissue integrity is maintained [14,15]. These
features include the blood–retinal barrier, the lack of MHC Class II posi-
tive professional antigen-presenting cells (APCs) [16,17], the absence of
a lymphatic drainage, the presence of soluble immunosuppressive fac-
tors secreted by ocular cells, such as TGF-β, FasL [18], PDL-1 [19], CTLA-
4 [20], CTLA-2 [21], CD200, CD55, CD46, and decay-accelerating factor
(DAF) [22,23], the constitutive expression of several of these regulatory
molecules, the generation of regulatory T cells [24–27], and ﬁnally, eye
antigen expression in the thymus that counteracts the escape of
autoreactive T cells into the peripheral blood [28].
Although many features of uveitis have been extensively studied,
therapeutic interventions that work in animal models have frequently
failed due to the heterogeneity of this disorder. Additionally, many of
the approaches are not disease-speciﬁc leading to enhancement of
local and systemic side-effects. Therefore, a precise diagnosis of the
type of uveitis is often needed to guarantee the best therapeutic control
of the progression of eye lesions. Diagnosis of AIU requires considering
multiple factors in the patient's history like age and the exclusion of in-
juries resulting from trauma, infections, or tumors, as well as a detailed
laboratory investigation, which should include complete blood count,
erythrocyte sedimentation rate, angiotensin converting enzyme and ly-
sozyme levels, serology for syphilis, HLA, and of course, ocular imaging
including fundoscopy [29]. Eligible treatments should also be addressed
aiming to minimize ocular complications that lead to decrease in visual
acuity and ultimatelymay cause irreversible blindness. Aggravating fea-
tures include cystoid macular edema, cataract, glaucoma, retinal vascu-
lar abnormalities, macular lesions, retinal detachment, corneal
opacities, optic-nerve atrophy, and phthisis that have also been fre-
quently reported [30].
Current treatments focus on immunosuppressive therapies to con-
trol acute inﬂammation and to ensure themaintenance of long-term re-
mission. Corticosteroids are usually among the ﬁrst chosen due to their
effectiveness at controlling inﬂammation both in the short term and in
the long term. However, a myriad of possible side effects (e.g. weight
gain, gastric ulceration, osteoporosis, ﬂuid retention, hypertension, dia-
betes mellitus, and changes in mental status) as well as ocular sequelae
(e.g. acceleration of cataract formation and glaucoma)may be observed.
More speciﬁc therapies have been associated with more positive effects
[31]. Such therapies include the prescription of antimetabolite drugs (in-
cluding Methotrexate, Azathioprine, Mycophenolate mofetil), T cell and
calcineurin inhibitors (cyclosporine, FK506/Tacrolimus), alkylating/
cytotoxic agents (cyclophosphamide, chlorambucil), intravenous immu-
noglobulin and modern immunobiologicals. The latter group includes
several agents, such as Inﬂiximab (a TNF-alpha antagonist mouse–
human chimeric antibody), Adalimumab (a human antibody developed
against TNF-alpha), Etanercept (another TNF-alpha antagonist, but less
efﬁcient than Inﬂiximab or Adalimumab), interleukin-2 receptor antag-
onists such as Daclizumab, as well as interferon-alpha based therapies
[32–34].
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gression of uveitis has been achieved, the search for safe andeffective al-
ternative therapies and disease-speciﬁc interventions are still going on
[31].
3. Animal models of autoimmune uveitis
Owing to their ability to reproduce speciﬁc features of human dis-
eases at diverse levels, from molecules to tissues and organs, animal
models have been increasingly used to gain understanding of the path-
ogenesis of several autoimmune diseases. However, despite the similar-
ities in molecular, morphological, and physiological aspects, a single
animal model will often lack the ability to adequately mimic the com-
plexity of mechanisms underlying a human disease. As a result, a num-
ber of models are usually combined to explain the many facets of
autoimmune disorders.
To this date, several animal models have been used to study AIU
(reviewed in [35,36]). In thenext sectionswe review themost frequent-
ly used models to study the immunopathogenesis as well as some
promising systems for evaluation of novel therapies.
3.1. Experimental autoimmune uveitis (EAU)
EAU is themost frequently used animal model of uveitis. This T-cell-
mediated intraocular inﬂammatory disease is predominantly induced
by immunization with the retinal antigens S-ag and IRBP coupled to
Complete Freund's Adjuvant (CFA) and a Bordetella pertussis toxin
(PTX) boost [37], with a 2-week time of onset. Inmice, the resulting dis-
ease is mainly conﬁned to the posterior part of the eye, with focal le-
sions affecting the retina and choroid. Vasculitis and the presence of
granulomas in the posterior layers of the eye are often seen and are ac-
companied by serous detachment of the retina and disorganization of
the photoreceptor layer. Severity of EAU is scored on a scale of 0 {no dis-
ease} to 4 {maximum disease} in half-point increments, according to a
semi quantitative system described previously [37], according to lesion
type, size, and number by histopathology examination of the eyes. Brief-
ly, the minimal criteria for scoring an eye as positive for uveitis is pres-
ence of inﬂammatory cell in the ciliary body, choroids, or retina (EAU
grade 0.5); progressive higher grades present discrete lesions in the
tissue such as vasculitis, granuloma formation, retinal folding and/or
detachment and photoreceptor damage [37].
Compared to other rodentmodels [38],mouse EAU is of longer dura-
tion and presents with recurrences, hence facilitating therapeutic han-
dling of the disease [37].
The genetic predisposition for the development of eye autoimmuni-
ty, where only some mice lineages are susceptible to the induction of
disease is quite clear in this model. Susceptibility is linked with speciﬁc
H-2MHChaplotypes, like H-2b found in C57BL/6 and C57BL/10mice, H-
2k found in B10.BR mice, and H-2r found in B10.RIII mice, with H-2r
being themost susceptible, followed byH-2k andH-2b [35]. EAU suscep-
tibility is also dependent on the pattern of immune response. For exam-
ple, strains prone to a more exacerbated TH1 response are more
susceptible than those with predominantly low TH1 responses [39].
As to the involvement of T-cell mediated inﬂammation cellular fea-
tures of EAU resemble those of the human disease. T cells are mainly
CD4+ exhibiting a TH1 phenotype in vivo [40], but are not required for
antigen priming and retinal damage. This is suggested by the observa-
tion that IFN-γ knockout mice mount a deviant immune response
against eye tissueswhen immunizedwith IRBP [41]. Although expected,
TH2 lymphocytes do not confer resistance to uveitis. Nevertheless, a bias
in the immune response towards the TH2 response proﬁle has been
shown to reduce pathogenic TH1 responses [39]. Recently, many groups
have shown the importance of TH17 cells in the pathogenesis of AIU
[42–44]. However it is difﬁcult to determine their real role in the estab-
lishment and maintenance of disease, as it seems that both TH1 and
TH17 cells can independently promote the disease onset [42].The importance of cytokines both in EAU and in human uveitis is in-
contestable, but the understanding of their precise effects is a matter of
great complexity. For example IFN-γ, the major cytokine of TH1 proﬁle,
is not required for onset and maintenance of EAU [41]. In addition, lack
of IL-17, the main product of TH17 lymphocytes, does not abrogate EAU
susceptibility either [44]. Therefore, it seems that the type of immune
response will be driven not by the presence or absence of a particular
cytokine, but by the balance of the cytokine milieu in the eye, which
comprises IL-1, IL-12, IL-23, IL-4, IL-10 and several others (reviewed in
[45]).
Altogether, these features make EAU an interesting animal model to
acquire further understanding on aspects of the immune regulation
taking place in the diseased eye.
3.2. Transgenic IRBP-speciﬁc T cell model of spontaneous EAU
Recently, a novel EAU model was developed to study basic autoim-
mune responses occurring in an immunoprivileged site such as the
eye [46,47]. This spontaneous model uses an IRBP161-180 peptide-
speciﬁc transgenic T cell receptor mouse model on a B10.RIII back-
ground, and shows the hallmarks of the human autoimmune uveitis
as judged by histology and fundoscopic analysis. The CD4+ T cells inﬁl-
trating the uveitic eyes were of an effector/memory phenotype, but the
inﬁltrate also included Th17 inﬂammatory and extrathymically-derived
regulatory T cells. According to the level of transgenes present in the T
cell population, disease severity varied. Additionally, in a classic adop-
tive transfer experiment IRBP-peptide activated Th1 cells could imple-
ment the disease in wild type naive recipients [46], according to the
level of transgene in each of the lineages. On the other hand, the time
course of the spontaneous disease in this model and also in Aire
knockout B10.RIII mice was longer, with an onset of about 6 weeks in-
stead of the usual 2 weeks in the original model [47]. Thus, even
when using the same retinal antigen, time courses, severity of the pa-
thology, and T cell proﬁles can be quite different, highlighting the vari-
ability of the disease.
3.3. Humanized model of EAU
Despite the usefulness of animal models in the understanding of
mechanisms underlying the pathogenesis of autoimmune diseases,
there are limitations regarding the speciﬁcity of effector cells or the ge-
netic background underlying disease development. This is particularly
important considering that AIU is more likely to be a group rather
than a single disease as disease course and clinical manifestations can
be highly heterogeneous. Genetic heterogeneity may underlie much of
this variation associated with the clinical disease. For instance, previous
evidence has shown a substantial degree of heterogeneity in the HLA
loci from patients diagnosed with the classical (not linked to Behçet's,
ankylosing spondylitis, or rheumatoid arthritis) autoimmune uveitis
[48]. HLA-DR4, HLA-DR3 and even some HLA-DQ alleles have been
linked with the pathogenesis of the disease in humans [49,50].
Humanized models have therefore been established in the last de-
cade as important tools for the study of eye immunology. For example,
although T cells frommany patients diagnosedwith autoimmune uveitis
respond to immunization with S-ag [51], there is currently no mouse
model exhibiting a similar response. Conversely, humanized HLA-DR3,
HLA-DR4, andHLA-DQ8 transgenicmice candevelop uveitis after immu-
nizationwith retinal antigens [12]. For example, HLA-DR3+mice devel-
op the disease following immunization with S-ag. Similarly, HLA-A29
transgenic mice have been also shown to spontaneously develop a reti-
nopathy resembling human birdshot chorioretinopathy [52].
Taken together, these models were important in the characteriza-
tion of MHC-class II antigen presentation in AIU and represent the bot-
tom line for studies aiming to identify relevant auto-antigenic epitopes
and the establishment of antigen-speciﬁc immunotherapies.
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In this animal model, uveitis is not induced by immunization with
any retinal antigen to trigger autoimmunity, suggesting that the ob-
served inﬂammatory response may be due to other mechanisms. In
Lewis rats, the induction is achieved by immunizationwith lipopolysac-
charide (LPS) [53] and in mice, immunization is carried out with a
Salmonella typhimurium endotoxin, indicating an important role for
the innate armof immune response. In both rodentmodels the resulting
disease is an anterior uveitis of short duration, which does not resemble
any speciﬁc human uveitis. Although this model does not duplicate all
the features of the human anterior uveitis, pathways activated during
the innate response can be elicited by its use. Hence, its importance dur-
ing disease onset, not only in the anterior uveitis but also in other types
of uveitis might as well be studied using this model.
3.5. Experimental melanin protein-induced uveitis
In this rat model of uveitis, the disease induction is achieved by im-
munizationwithmelanin protein in CFA orHunter's Adjuvant and a PTX
boost [54–56]. The resulting disease is characterized by inﬁltration and
damage of the anterior portion of the eye by CD4+ and CD8+ T cells,
macrophages and neutrophils. Clinical manifestations start approxi-
mately 14 days after disease induction and are very similar to those
found in human anterior uveitis, including iritis and iridocyclitis, but
with no retinal commitment.
This model comprises important innate immune response features
and has been useful to clarify the role of nitric oxide (NO) in eye inﬂam-
mation [56], to evaluate speciﬁc therapies aiming at the NO pathway,
and even to achieve a better understanding of the differences between
anterior and posterior uveitis.
3.6. TAM-receptor knockout mice
The TAM family of receptor tyrosine kinases is involved in the con-
trol of dendritic cell cytokine signaling [57] and the knockout of three
receptors of this family (TAM TKO) has been shown to lead to multi-
organ autoimmune disease in mice [58]. Recently, Ye and colleagues
demonstrated that TAM TKO mice usually develop eye inﬂammation
and are more susceptible to immunization with IRBP peptides. These
mice show postnatal degeneration of the ocular photoreceptor layer
and cellular inﬁltration by T lymphocytes and macrophages. Moreover,
IRBP-speciﬁc T lymphocytes are found in these mice, explaining their
high susceptibility to the development of uveitis even when induced
by low doses of IRBP [59].
As in this model disease develops spontaneously it may provide an
important tool to understand the role of the environment in overall
vulnerability for autoimmunity in the eye. It may also help unravel the
contribution of a deregulated population of APCs to the onset andmain-
tenance of disease.
4. Immunomodulation strategies for non-infectious uveitis
Strategies focusing on diverse immunomodulatory targets for treat-
ment of autoimmune diseases have been reported in humans and in ex-
perimental models. The main goal of these approaches is to control the
acute immune and inﬂammatory responses and to dampen chronic re-
sponses. These avenues have been explored also in inﬂammatory ocular
disorders [60]. Furthermore, exploratory research and clinical trials
have targeted either the blockade of effector pathways or of their com-
panion co-stimulatory molecules at different checkpoints of the im-
mune response. Examples of targets evaluated are T cell receptors
(CD3), their costimulatory receptors (CD28, CTLA-4) and corresponding
ligands (B7-1 and B7-2, also known as CD80 and CD86), and cytokines
like IL-2 and their receptors. Here, we summarize the available evidence
on effectiveness of these treatments in human and experimental uveitis.4.1. The IL-2/IL-2R pathway
IL-2 is a 15 kDa α-helical cytokine produced predominantly by acti-
vated T lymphocytes. It binds to the IL-2 receptor (IL-2R), which is
formed by three subunits: α (CD25), β (CD122), and the common γ
(CD132) chains (reviewed in [61]).
IL-2 has several functions in the development and maintenance of
the immune system. Initially, this cytokine was known for its ability to
promote the growth and clonal expansion of all T cells. However,
many years of research have shown that IL-2 is also essential for the
maintenance of regulatory T cells in the periphery and for the control
of TH17 and follicular helper T cells (reviewed in [62]).
Because of such a central role in the control of the immune response,
many efforts have targeted the IL-2 pathway as a means to control dis-
ease progression. By the time the ﬁrst studies using IL-2 blockade or chi-
meric IL-2 toxins were conducted using experimental models of
autoimmune disease, it was already known that a large proportion of
eye-inﬁltrating cells in an EAU model bore high amounts of IL-2R [63].
These facts led Roberge and colleagues to inhibit EAU with an IL-2 chi-
meric toxin [64]. If treatment was initiated 7 or 10 days after induction
of disease this therapy resulted in lesser incidence and disease severity
in a rat EAU model. The efﬁcacy of this approach was then conﬁrmed
with monoclonal antibodies directed against IL-2R [65,66].
In humans, treatment became available with a humanized antibody
directed against the α chain of the IL-2R (Daclizumab). At ﬁrst, a phase
I/II clinical trial was conducted, which showed that following
12 months of Daclizumab, 8 of 10 patients diagnosed with chronic se-
vere sight-threatening intermediate and posterior uveitis had their dis-
ease under control and immunosuppressive agent dosage could be
abatedwith nomajor side effects. In some cases of anterior uveitis, how-
ever, patients responded to cyclosporin but not to Daclizumab, suggest-
ing that different mechanisms are involved in this subtype of uveitis
[67]. Subsequent clinical trials have achieved similar results [68–70],
supporting the use of Daclizumab as a valid immunotherapy for some,
but not all AIU patients.
4.2. Anti-CD3 therapy
Based on a similar rationale, namely aiming at a widespread down-
regulation of effector T cell responses, antibodies targeting CD3 mole-
cules have been the focus of research on treatment of autoimmune
disorders since the ﬁrst antibody speciﬁc for humans was produced in
1979, by Kung and Goldstein [71]. Anti-CD3-induced tolerance has
long been investigated (reviewed in [72]). Continuous research efforts
directed towards the production of safer anti-CD3 antibodies, such as
the humanized antibodies withmutated Fc regions, as well as extensive
work on tolerance induction, led anti-CD3 antibodies to form a new cat-
egory of immunotherapeutic agents used to treat autoimmune diseases
as well as to ensure long-term survival of organ allografts [72].
In animal models, the use of oral anti-CD3 was able to suppress ex-
perimental autoimmune encephalomyelitis in a mouse model that
could be explained by the induction of CD4+CD25−LAP+ regulatory T
cells in a TGF-β-dependent fashion [73]. Additionally, the use of nasal
anti-CD3 ameliorated systemic lupus erythematosus in two different
mice models by inducing IL-10. In this case IL-10 was secreted by
CD4+CD25−LAP+ regulatory cells, which downregulated follicular
helper T cells and probably led to the observed tolerance [74]. Success
using anti-CD3 was also obtained in animal models of diabetes [75,76].
In humans, clinical improvement of type 1 diabetic patients was ob-
served after treatment with an anti-CD3 monoclonal antibody
(hOKT3γ1(Ala-Ala); Teplizumab) and did not require use of any other
immunosuppressive treatment during a 2-year follow-up [77]. Like-
wise, psoriatic arthritis patients treated with a similar anti-CD3 anti-
body showed better clinical outcome after a two-week treatment [78].
Despite thewidespreaduse of anti-CD3 to treat autoimmunity, there
is only one study testing its effectiveness in uveitis. Using the EAU
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CD3 was able to ameliorate disease. The anti-CD3 used was directed
against the invariant CD3ε chain and was unable to bind Fc receptors.
The antibody given intraperitoneally for 6 or 10 days after disease in-
duction was able to suppress EAU development in both treatment
schemes, indicating its effectiveness during disease onset and upon
priming of T cells. Additionally, long-term tolerance in the treated
mice was achieved.
Although further research is needed to conﬁrm these ﬁndings for
other treatment schemes (such as different administration routes or
under the association with other immunomodulatory drugs), the re-
sults indicate that anti-CD3 might be a promising immunotherapy for
the treatment of uveitis. An important issue remaining concerns the ad-
verse effects caused by CD3 treatment, the development of anti-drug
antibodies, and the contrasting results obtained in preclinical and clini-
cal trials [80,81].
4.3. The CD28, CTLA4, and B7 costimulation trinity
CD28, a membrane protein belonging to the well-known family of
co-stimulatory molecules, transduces signals, which act synergistically
as a second signal with the T cell receptor complex to activate naïve T
cells. CD28 is constitutively expressed in most of CD4+ and in 50% of
CD8+ T cells in humans; additionally, it is found in all mouse naïve T
cells [82]. The CD28 co-stimulator receptor is a homodimer structured
by disulﬁde bonds on the T cell surface that binds to the B7-1 (CD80),
B7-2 (CD86), and ICOS-L (B7RP1) molecules expressed in activated
APCs [83,84]. B7-1 and B7-2 receptors are up-regulated by inﬂammato-
ry as well as antigen-speciﬁc signals and act as ligands for both CD28
and cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) expressed
on T cells [83].
CD28 enhances distinct T cell responses, which include survival and
clonal expansion, IL-2 cytokine production, and naïve T cell differentia-
tion into effector and memory phenotypes. In fact, there have been
many reports on successful immunosuppression achieved by the block-
ade of the CD28/B7 pathway during treatment of autoimmune diseases,
rejection of grafted organs, and in graft versus host disease [85]. Howev-
er, the importance of pre-clinical and clinical studies even with promis-
ing therapeutic agents are highlighted by the extremely severe events
that occurred during the phase I study of the superagonistic anti-CD28
antibody TGN1412 in six healthy human volunteers. The treatment
caused massive trapping of T cells in spleen and lymph nodes in
both rats and men, but the human volunteers, differently from the
non-human primates tested suffered a massive cytokine storm and
multiorgan failure which counteracted the possible beneﬁts derived
from the expected induction of regulatory T cells [86,87].
CTLA-4 (CD152) is structurally very similar to CD28, but differs in
the binding afﬁnity and temporal expression (reviewed by [85]). It is
constitutively expressed on the surface of regulatory T cells and is in-
duced upon activation of CD4+ and CD8+ T lymphocytes [88,89] and
is responsible for inhibiting the CD28-induced signals to competitively
downregulate and ultimately block the T cell response by speciﬁc bind-
ing to B7. Accordingly, CTLA-4 knockout mice present enhanced T cell
activation and proliferation and an increased incidence of systemic au-
toimmunity [90].
Due to the fact that both CTLA-4 andCD28 recognize and act through
the same B7 molecules expressed on the surface of APCs, the opposite
signals generated by these costimulatory molecules have been the
focus of many studies. CTLA-4 blockade with monoclonal antibodies
such as Ipilimumab and Tremelimumab leads to increased effector T
cell activity and this approach is being used in several types of malig-
nancies (reviewed in [91,92]), in both pre-clinical and clinical studies.
In other words, the contrasting effects induced by blockade of CD28
and CTLA-4 conﬁrm that, in the latter case, the approach does not
apply to treatment of autoimmune diseases. Indeed, colitis was one of
the more common adverse effects associated with this treatment [91].Inhibition of immune responses via blockade of the CD28 receptor
B7 (CD80 and CD86), however, remains a valid option for autoimmune
diseases, and is being explored through the use of Abatacept (CTLA-4-
Ig), a second generation recombinant fusion protein consisting of
CTLA-4 and a modiﬁed Fc fragment of human IgG1 [93,94] that binds
to both CD80 and CD86. Abatacept is approved by the Food and Drug
Administration (FDA) for treatment of rheumatoid arthritis and juvenile
idiopathic arthritis [94,95] and shows promising results in the case of
systemic lupus erythematosus (SLE) patients [93].
It has become apparent however, that due to its capacity to bind
both receptors, Abatacept blocks not only the CD28-mediated activation
of effector cells, but also an important subset of regulatory T cells which
function through CTLA4–CD80 signal transduction (reviewed in [96]). A
newer generation of CTLA-4Ig antibodies addresses the issue of the dou-
ble CD28 and CTLA-4 blockade aiming to enhance preferential binding
of the therapeutic antibody to CD86 over CD80 [97]. This version
(LEA29Y) of the molecule carries two amino acid changes and has
been developed trying to increase the binding avidity for CD86 [98,
99]. This change may be important because CD86 appears to be the
dominant costimulatory ligand in a number of experimental models
and, in treating mouse models of autoimmune disease, inhibition via
CD86 was more effective than inhibition via CD80.
There are only few reports on the role of the CD28/B7 pathway in oc-
ular autoimmune conditions that suggest CD28 may be a promising
molecule for the treatment of AIU [97]. One of the trials [100] showed
a percentual increase in co-stimulatory molecules, that is, of CD28, B7-
1, and B7-2 positive cells in the eye biopsies of patients with ocular cic-
atricial pemphigoid (OCP), a chronic autoimmune disease affectingmu-
cosal areas, including ocular (which represent about 70% of cases) and
skin manifestations [101]. Authors suggested that these molecules con-
tribute to the sustained immune activation in the OCP conjunctiva.
Intervention with anti-B7 antibodies was tested in EAU B10.A mice
and led to disease remission [102]. Data were conﬁrmed in an elegant
study showing the efﬁcacy of a combined anti-B7-1 and B7-2 treatment.
Authors complemented these experiments evaluating the protection
against EAU in B10.A mice in vivo with anti-CD28 antibodies. However,
although these approaches were able to control effector immune re-
sponses they failed to reverse disease when mice were challenged
with IRBP [103]. In another study, CTLA-4-Ig signiﬁcantly decreased
the average score when compared to saline-treated animals in an EAU
model [104]. Additionally, Abatacept was shown to abrogate eye in-
ﬂammation in cases of JIA-associated uveitis [105,106]. Taken together,
theseﬁndings support promising resultswith CTLA-4Ig in the treatment
of ocular autoimmune disorders.
4.4. Blockade of other co-stimulatory pathways
Blockade with other co-stimulatory molecules such as ICOS and PD-
1 have also been essayed, with variable results.
PD-1 is a receptor broadly expressed in T and B cells and is involved
in limiting T cell responses, and thereforemay have a role in autoimmu-
nity scenarios [91,107]. As occurs with CTLA-4:B7 the blockade of PD-1:
PD-L1 leads to an enhancement of T cell activity, and is being explored
in cancer therapy [108]; the ﬁrst trials in humans with the BMS-
936558 antibody were recently concluded [91,108]. In contrast, the
use of surrogate PD1 ligands was shown to induce immunosuppression
in multiple sclerosis [109], autoimmune glomerulonephritis [110], and
SLE mouse models [111]. However, no studies on ocular autoimmunity
have been carried out up to this date.
ICOS is also a co-stimulatory molecule from the CD28 family, but
does not bind strongly to either B7-1 or B7-2 [84]. Instead, the major
ICOS ligand is B7RP-1 and its engagement enhances cell activation and
stimulates theproduction of inﬂammatory cytokines [112]. Accordingly,
ICOS:B7RP-1 blockade dampened autoimmunity in experimental auto-
immune encephalitis [113], in a (NZBxNZW)F1 mouse model of SLE
[114], and in EAU [115]. The current understanding of overall T cell-
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to a minor role of these pathways, and CD28 blockade remains a
major therapeutic target.4.5. Blockade with anti-CD28 Fab′ fragment
A recurrent issue in all these studies is the overlapping proﬁle of
therapeutic antibodies like Abatacept that bind to both CD80 and
CD86, interrupting the function not only of the pro-inﬂammatory path-
ogenic T cells, but also of the protective regulatory T cells. Furthermore,
as CTLA-4 is crucial for downregulation of the same T cells activated via
CD28 costimulation, the outcome of trials with these antibodies can be
quite disappointing. Ideally, a molecule should be effective in blocking
CD28-based signal transduction while bypassing CTLA-4.
Therefore, exploratory research on the CD28 molecule has
attempted to generate more speciﬁc effects, avoiding interference
with the closely related CTLA-4. As CTLA-4 is a major player in the
downregulation of the immune response mediated by the subpopula-
tion of regulatory T cells, a directed inactivation via CD28 of effector T
cells could result in a concomitant enhancement of the Treg population.
The increase in molecule speciﬁcity might also favor long-term effects
and increased intervals between intakes of the therapeutic products
leading to safer immunobiological compounds to intervene in chronic
degenerative processes [116].
Efﬁmune, a French Biotech Company is developing a novel molecule
that targets CD28 [117–119]. FR104, a CD28 antagonistmonovalent Fab′
antibody, has shown preclinical efﬁcacy suppressing effector T cells
while enhancing regulatory T cell function and immune tolerance in a
humanized GVHD mice model [120]. There is evidence that FR104
does not act upon the inhibitory CTLA-4 and PDL-1 pathways, as evi-
denced by the increased frequency of CD4highCD127low FoxP3, i.e. regu-
latory T cells in the peripheral blood [120]. This novel humanized
pegylated Fab′ antibody fragment presented a long half-life in monkeys
and was proven immunologically safe. All these features make FR104 a
good candidate for further preclinical and clinical investigations on
different autoimmune conditions.
FR104 is currently under study by an European Community-
sponsored multicentric group of researchers (project TRIAD — for more
information see https://www.triad-cd28.eu/efﬁmune.php, updated 12/
11/2013), in which our team participates studying the effect on the
mouse model of EAU on the B10.RIII background as described below.
B10.RIIImicewere immunized subcutaneouslywith the IRBP 161-180
peptide emulsiﬁed inComplete Freund's Adjuvant, plus a B. pertussis toxin
boost and were then treated with the murine FR104 analog mPEG-
PV1Fab′ (PV1) after the onset of disease. Histopathology analysis showed
that the general disease score was signiﬁcantly lower in the PV1-treated
group when compared with its untreated counterpart and an impact
upon incidence of the disease was also observed in the PV1-treated
group. This effect seemed to correlate with higher frequencies of naïve TFig. 1. Summarizes the preliminary data from our group showing that in an autoimmune uveiti
vere diseasewhen compared to untreatedmice.Moreover, this effect seems to be associatedwit
the CD28 blockade by this novel Fab′ ´CD28 antagonist prevents a full activation of T cells, rend
enedmemory formation. Thus, the T cells from treatedmice inﬁltrate the eyes but cannot induce
against disease progression.lymphocytes inﬁltrating the eyes of themice and lower frequencies of ac-
tivated T cells (results not shown). Thus, treatment with PV1 might be
modulating T cell activation and memory generation (Fig. 1). These pre-
liminary results are highly encouraging and indicate that blockade of
CD28 signaling in autoimmune uveitis with this novel immunobiological
may become an additional therapeutical option.
5. Conclusion
There is great interest in the understanding of the mechanisms in-
volved in the initiation and progression of autoimmune diseases, partic-
ularly in light of the need to uncover novel andmore speciﬁc treatments
targeted at the modulation of key molecules involved in disease patho-
genesis. Additionally, individual approaches that take into account
speciﬁc immunological proﬁles are ideal to improve therapeutic effec-
tiveness and prevent systemic and non-related side effects associated
with available immunosuppressive therapies.
The present review shows that current research onAIU is diversiﬁed,
aiming atmultiple aspects of disease pathogenesis. As T cells have a cen-
tral participation in the development of uveitis, encompassing the rec-
ognition of retinal antigens to the genesis of immunological memory,
intervention schemes focused on lymphocyte signaling pathways are
encouraging. Among them, the more promising strategies are targeted
at the IL-2 cytokine involved in disease progression and also at the
CD28/B7 molecular pathway, bypassing the antagonistic CTLA-4 signal
transduction.
Take-home messages
• Autoimmune uveitis is a T-cell mediated disease caused by immune
responses against ocular arrestin, interphotoreceptor retinoid binding
protein and/or recoverin.
• Experimental autoimmune uveitis in genetically susceptible mice ex-
hibits focal lesions affecting retina and choroid, with vasculitis and
granulomas, serous detachment of the retina and disorganization of
the photoreceptor layer.
• Research and clinical trials aim at the blockade of effector pathways or
of their companion co-stimulatory molecules, such as CD3 T cell re-
ceptors and their costimulatory CD28, CTLA-4 receptors and corre-
sponding ligands, and the IL-2 pathway.
• FR104, a CD28 antagonist monovalent Fab′ antibody, has shown pre-
clinical efﬁcacy suppressing effector T cells while enhancing regulato-
ry T cell function and immune tolerance in autoimmune disease
models.
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